Metastatic Leiomyosarcoma: Clinical Trials

8 trials for Metastatic Leiomyosarcoma, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 completed, 2 recruiting, 2 terminated, 1 active not recruiting. 8 Phase 2, 3 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 28Completed 2, Recruiting 2, Terminated 2, Active not recruiting 1, Withdrawn 1
Phase 13Terminated 2, Recruiting 1

Follow Metastatic Leiomyosarcoma: new trials by email Literature Review of Metastatic Leiomyosarcoma trials Research Report on Metastatic Leiomyosarcoma

Trials (filtered) newest first · largest first

All 8 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma
Abemaciclib, Biopsy Procedure, Biospecimen Collection - Advanced Dedifferentiated Liposarcoma, Advanced Leiomyosarcoma
Phase 1 / Phase 2RecruitingNational Cancer Institute (NCI)742026-03-182026-10-21
XL092 (Zanzalintinib) for the Treatment of Patients With Metastatic or Unresectable Leiomyosarcoma, Bone Sarcoma or Translocation-associated Soft Tissue Sarcoma
Biospecimen Collection, Computed Tomography, Echocardiography - Metastatic Leiomyosarcoma, Unresectable Leiomyosarcoma
Phase 2RecruitingNorthwestern University732024-09-192026-10-13
Niraparib for the Treatment of Leiomyosarcoma
Niraparib Tosylate Monohydrate - Locally Advanced Leiomyosarcoma, Metastatic Leiomyosarcoma
Phase 2WithdrawnDavid Liebner, MD2023-12-012023-09-18
Cabozantinib and Temozolomide for the Treatment of Unresectable or Metastatic Leiomyosarcoma or Other Soft Tissue Sarcoma
Cabozantinib, Quality-of-Life Assessment, Questionnaire Administration - Metastatic Leiomyosarcoma, Metastatic Soft Tissue Sarcoma
Phase 2Active not recruitingCity of Hope Medical Center962020-01-222026-11-03
Avelumab and Trabectedin in Treating Patients With Liposarcoma or Leiomyosarcoma That is Metastatic or Cannot Be Removed by Surgery
Avelumab, Trabectedin - Metastatic Leiomyosarcoma, Metastatic Liposarcoma
Phase 1 / Phase 2TerminatedFred Hutchinson Cancer Center352017-09-282022-04-29
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
Pazopanib, Pazopanib Hydrochloride, Sapanisertib - High Grade Sarcoma, Metastatic Leiomyosarcoma
Phase 1 / Phase 2TerminatedNational Cancer Institute (NCI)1512015-11-302022-08-23
SARC018: A Study of Mocetinostat and Gemcitabine in Patients With Metastatic Leiomyosarcoma
Mocetinostat, Gemcitabine - Metastatic Leiomyosarcoma
Phase 2CompletedSarcoma Alliance for Research through Collaboration202015-11-122019-01-29
Nivolumab Alone or in Combination With Ipilimumab in Treating Patients With Advanced Uterine Leiomyosarcoma
Ipilimumab, Laboratory Biomarker Analysis, Nivolumab - Metastatic Leiomyosarcoma, Unresectable Leiomyosarcoma
Phase 2CompletedNational Cancer Institute (NCI)202015-05-192025-02-25

Narrower conditions

Leiomyosarcoma (8)  ·  Liposarcoma (2)  ·  Sarcoma (2)  ·  Sarcoma, Synovial (2)  ·  Bone Neoplasms (1)  ·  Dermatofibrosarcoma (1)  ·  Histiocytoma, Malignant Fibrous (1)  ·  Neurofibrosarcoma (1)  ·  Osteosarcoma (1)  ·  Sarcoma, Ewing (1)

Broader conditions

Neoplasms (8)  ·  Neoplasms by Histologic Type (8)  ·  Neoplasms, Connective and Soft Tissue (8)  ·  Neoplasms, Muscle Tissue (8)  ·  Sarcoma (6)  ·  Neoplasms, Adipose Tissue (2)  ·  Neoplasms, Connective Tissue (2)  ·  Bone Diseases (1)  ·  Fibrosarcoma (1)  ·  Histiocytoma (1)  ·  Musculoskeletal Diseases (1)  ·  Neoplasms by Site (1)  ·  Neoplasms, Bone Tissue (1)  ·  Neoplasms, Fibrous Tissue (1)  ·  Neoplasms, Nerve Tissue (1)

Interventions

Gemcitabine (2)  ·  Specimen Handling (2)  ·  Biopsy (1)  ·  CTLA-4 Antigen (1)  ·  Docetaxel (1)  ·  Ipilimumab (1)  ·  Nivolumab (1)  ·  Temozolomide (1)  ·  Trabectedin (1)  ·  abemaciclib (1)  ·  avelumab (1)  ·  cabozantinib (1)  ·  mocetinostat (1)  ·  niraparib (1)  ·  pazopanib (1)

Sponsors

National Cancer Institute (NCI) (3)  ·  City of Hope Medical Center (1)  ·  David Liebner, MD (1)  ·  Fred Hutchinson Cancer Center (1)  ·  Northwestern University (1)  ·  Sarcoma Alliance for Research through Collaboration (1)

Countries

United States (7)

Top investigators

David Liebner, MD (1)  ·  Edwin Choy, MD, PhD (1)  ·  Elise F Nassif (1)  ·  Janet Yoon, MD (1)  ·  Pedro Hermida de Viveiros, MD (1)  ·  Seth Pollack (1)  ·  Shreyas Patel, MD (1)  ·  Suzanne George (1)  ·  William D Tap (1)

Results publications

PMID 41554272

NIH funding

P30CA060553 (2), P30CA015704 (1), U10CA180821 (1), UM1CA186688 (1), UM1CA186709 (1)